{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:46:19Z","timestamp":1792691179199,"version":"4.5.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-50931-8","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T19:02:45Z","timestamp":1722538965000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["The small molecule inhibitor of SARS-CoV-2 3CLpro EDP-235 prevents viral replication and transmission in vivo"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4032-7545","authenticated-orcid":false,"given":"Michael H. J.","family":"Rhodin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archie C.","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5778-3857","authenticated-orcid":false,"given":"Anand","family":"Balakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nalini","family":"Bisht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce Sweeney","family":"Gibbons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Vaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Cressey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda","family":"Crepeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruichao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Manalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel E.","family":"Levene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianzhu","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kellye","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0620-1674","authenticated-orcid":false,"given":"Robert M.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin M.","family":"Lieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2507-6944","authenticated-orcid":false,"given":"Josef D.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2034-2107","authenticated-orcid":false,"given":"Richard K.","family":"Plemper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4989-5381","authenticated-orcid":false,"given":"Sarah R.","family":"Leist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Scobey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6827-8701","authenticated-orcid":false,"given":"Ralph S.","family":"Baric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Goodwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yat Sun","family":"Or","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,1]]},"reference":[{"key":"50931_CR1","unstructured":"World Health Organization. Coronavirus disease (COVID-19). (2023)."},{"key":"50931_CR2","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","volume":"22","author":"G Li","year":"2023","unstructured":"Li, G., Hilgenfeld, R., Whitley, R. & De Clercq, E. Therapeutic strategies for COVID-19: progress and lessons learned. Nat. Rev. Drug Discov. 22, 449\u2013475 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"50931_CR3","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","volume":"386","author":"J Hammond","year":"2022","unstructured":"Hammond, J. et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N. Engl. J. Med. 386, 1397\u20131408 (2022).","journal-title":"N. Engl. J. Med."},{"key":"50931_CR4","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa2116044","volume":"386","author":"A Jayk Bernal","year":"2022","unstructured":"Jayk Bernal, A. et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N. Engl. J. Med. 386, 509\u2013520 (2022).","journal-title":"N. Engl. J. Med."},{"key":"50931_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07639-1","volume":"22","author":"L Matrajt","year":"2022","unstructured":"Matrajt, L., Brown, E. R., Cohen, M. S., Dimitrov, D. & Janes, H. Could widespread use of antiviral treatment curb the COVID-19 pandemic? A modeling study. BMC Infect. Dis. 22, 683 (2022).","journal-title":"BMC Infect. Dis."},{"key":"50931_CR6","doi-asserted-by":"publisher","first-page":"e230046","DOI":"10.1001\/jamahealthforum.2023.0046","volume":"4","author":"M Khunte","year":"2023","unstructured":"Khunte, M., Kumar, S., Salomon, J. A. & Bilinski, A. Projected COVID-19 Mortality Reduction From Paxlovid Rollout. JAMA Health Forum 4, e230046 (2023).","journal-title":"JAMA Health Forum"},{"key":"50931_CR7","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1093\/cid\/ciac933","volume":"76","author":"H Mukae","year":"2023","unstructured":"Mukae, H. et al. Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2\/3 Study. Clin. Infect. Dis. 76, 1403\u20131411 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"50931_CR8","doi-asserted-by":"publisher","first-page":"6595","DOI":"10.1021\/acs.jmedchem.5b01461","volume":"59","author":"T Pillaiyar","year":"2016","unstructured":"Pillaiyar, T., Manickam, M., Namasivayam, V., Hayashi, Y. & Jung, S.-H. An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy. J. Med. Chem. 59, 6595\u20136628 (2016).","journal-title":"J. Med. Chem."},{"key":"50931_CR9","doi-asserted-by":"publisher","first-page":"13190","DOI":"10.1073\/pnas.1835675100","volume":"100","author":"H Yang","year":"2003","unstructured":"Yang, H. et al. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc. Natl. Acad. Sci. USA 100, 13190\u201313195 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"50931_CR10","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1099\/0022-1317-81-4-853","volume":"81","author":"J Ziebuhr","year":"2000","unstructured":"Ziebuhr, J., Snijder, E. J. & Gorbalenya, A. E. Virus-encoded proteinases and proteolytic processing in the Nidovirales. J. Gen. Virol. 81, 853\u2013879 (2000).","journal-title":"J. Gen. Virol."},{"key":"50931_CR11","first-page":"95","volume":"7","author":"Z Lv","year":"2015","unstructured":"Lv, Z., Chu, Y. & Wang, Y. HIV protease inhibitors: a review of molecular selectivity and toxicity. HIV AIDS (Auckl.) 7, 95\u2013104 (2015).","journal-title":"HIV AIDS (Auckl.)"},{"key":"50931_CR12","first-page":"Doc08","volume":"5","author":"P de Leuw","year":"2017","unstructured":"de Leuw, P. & Stephan, C. Protease inhibitors for the treatment of hepatitis C virus infection. GMS Infect. Dis. 5, Doc08 (2017).","journal-title":"GMS Infect. Dis."},{"key":"50931_CR13","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","volume":"582","author":"Z Jin","year":"2020","unstructured":"Jin, Z. et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature 582, 289\u2013293 (2020).","journal-title":"Nature"},{"key":"50931_CR14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.virol.2023.02.011","volume":"581","author":"S Kandwal","year":"2023","unstructured":"Kandwal, S. & Fayne, D. Genetic conservation across SARS-CoV-2 non-structural proteins - Insights into possible targets for treatment of future viral outbreaks. Virology 581, 97\u2013115 (2023).","journal-title":"Virology"},{"key":"50931_CR15","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1126\/science.1085658","volume":"300","author":"K Anand","year":"2003","unstructured":"Anand, K., Ziebuhr, J., Wadhwani, P., Mesters, J. R. & Hilgenfeld, R. Coronavirus Main Proteinase (3CLpro) Structure: Basis for Design of Anti-SARS Drugs. Science 300, 1763\u20131767 (2003).","journal-title":"Science"},{"key":"50931_CR16","unstructured":"Antiviral and Antibody Products Summary Recommendations. COVID-19 Treatment Guidelines https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/antivirals-including-antibody-products\/summary-recommendations\/."},{"key":"50931_CR17","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1126\/science.abl4784","volume":"374","author":"DR Owen","year":"2021","unstructured":"Owen, D. R. et al. An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19. Science 374, 1586\u20131593 (2021).","journal-title":"Science"},{"key":"50931_CR18","doi-asserted-by":"publisher","first-page":"9866","DOI":"10.3390\/ijms23179866","volume":"23","author":"NHC Loos","year":"2022","unstructured":"Loos, N. H. C., Beijnen, J. H. & Schinkel, A. H. The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism? Int. J. Mol. Sci. 23, 9866 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"50931_CR19","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1124\/dmd.121.000801","volume":"50","author":"H Eng","year":"2022","unstructured":"Eng, H. et al. Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans. Drug Metab. Dispos. 50, 576\u2013590 (2022).","journal-title":"Drug Metab. Dispos."},{"key":"50931_CR20","unstructured":"Pfizer Announces Additional Phase 2\/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death | Pfizer. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-announces-additional-phase-23-study-results."},{"key":"50931_CR21","unstructured":"Lam, C. & Patel, P. Nirmatrelvir-Ritonavir. in StatPearls (StatPearls Publishing, Treasure Island (FL), 2023)."},{"key":"50931_CR22","doi-asserted-by":"publisher","first-page":"e3000003","DOI":"10.1371\/journal.pbio.3000003","volume":"16","author":"S Duffy","year":"2018","unstructured":"Duffy, S. Why are RNA virus mutation rates so damn high? PLoS Biol. 16, e3000003 (2018).","journal-title":"PLoS Biol."},{"key":"50931_CR23","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41579-022-00809-7","volume":"21","author":"M Cox","year":"2023","unstructured":"Cox, M. et al. SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies. Nat. Rev. Microbiol. 21, 112\u2013124 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"50931_CR24","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.cell.2021.12.032","volume":"185","author":"M Hoffmann","year":"2022","unstructured":"Hoffmann, M. et al. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. Cell 185, 447\u2013456.e11 (2022).","journal-title":"Cell"},{"key":"50931_CR25","doi-asserted-by":"publisher","first-page":"944","DOI":"10.3390\/v15040944","volume":"15","author":"NZ Zabidi","year":"2023","unstructured":"Zabidi, N. Z. et al. Evolution of SARS-CoV-2 Variants: Implications on Immune Escape, Vaccination, Therapeutic and Diagnostic Strategies. Viruses 15, 944 (2023).","journal-title":"Viruses"},{"key":"50931_CR26","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1080\/07853890.2022.2031274","volume":"54","author":"Q Fernandes","year":"2022","unstructured":"Fernandes, Q. et al. Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines. Ann. Med. 54, 524\u2013540 (2022).","journal-title":"Ann. Med."},{"key":"50931_CR27","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41586-022-05514-2","volume":"613","author":"S Iketani","year":"2023","unstructured":"Iketani, S. et al. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. Nature 613, 558\u2013564 (2023).","journal-title":"Nature"},{"key":"50931_CR28","doi-asserted-by":"publisher","unstructured":"Zuckerman, N. S., Bucris, E., Keidar-Friedman, D., Amsalem, M. & Brosh-Nissimov, T. Nirmatrelvir resistance - de novo E166V\/L50V mutations in an immunocompromised patient treated with prolonged nirmatrelvir\/ritonavir monotherapy leading to clinical and virological treatment failure - a case report. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciad494. (2023).","DOI":"10.1093\/cid\/ciad494"},{"key":"50931_CR29","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1021\/acsinfecdis.3c00125","volume":"9","author":"JM Flynn","year":"2023","unstructured":"Flynn, J. M. et al. Systematic Analyses of the Resistance Potential of Drugs Targeting SARS-CoV-2 Main Protease. ACS Infect. Dis. 9, 1372\u20131386 (2023).","journal-title":"ACS Infect. Dis."},{"key":"50931_CR30","doi-asserted-by":"publisher","first-page":"e0281522","DOI":"10.1128\/mbio.02815-22","volume":"14","author":"D Jochmans","year":"2023","unstructured":"Jochmans, D. et al. The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir. mBio 14, e0281522 (2023).","journal-title":"mBio"},{"key":"50931_CR31","doi-asserted-by":"publisher","first-page":"eadd7197","DOI":"10.1126\/sciadv.add7197","volume":"8","author":"Y Zhou","year":"2022","unstructured":"Zhou, Y. et al. Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system. Sci. Adv. 8, eadd7197 (2022).","journal-title":"Sci. Adv."},{"key":"50931_CR32","doi-asserted-by":"publisher","first-page":"eabq7360","DOI":"10.1126\/scitranslmed.abq7360","volume":"15","author":"E Heilmann","year":"2023","unstructured":"Heilmann, E. et al. SARS-CoV-2 3CL pro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376. Sci. Transl. Med. 15, eabq7360 (2023).","journal-title":"Sci. Transl. Med."},{"key":"50931_CR33","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41586-022-04788-w","volume":"607","author":"CJ Carlson","year":"2022","unstructured":"Carlson, C. J. et al. Climate change increases cross-species viral transmission risk. Nature 607, 555\u2013562 (2022).","journal-title":"Nature"},{"key":"50931_CR34","doi-asserted-by":"publisher","first-page":"100029","DOI":"10.1016\/j.ecochg.2021.100029","volume":"2","author":"MF Gebara","year":"2021","unstructured":"Gebara, M. F., May, P. H. & Platais, G. Pandemics, conservation, and human-nature relations. Clim. Change Ecol. 2, 100029 (2021).","journal-title":"Clim. Change Ecol."},{"key":"50931_CR35","unstructured":"Human Coronavirus Types | CDC. https:\/\/www.cdc.gov\/coronavirus\/types.html (2021)."},{"key":"50931_CR36","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1093\/cid\/ciab456","volume":"74","author":"AN Vlasova","year":"2022","unstructured":"Vlasova, A. N. et al. Novel Canine Coronavirus Isolated from a Hospitalized Patient With Pneumonia in East Malaysia. Clin. Infect. Dis. 74, 446\u2013454 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"50931_CR37","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41586-021-04111-z","volume":"600","author":"JA Lednicky","year":"2021","unstructured":"Lednicky, J. A. et al. Independent infections of porcine deltacoronavirus among Haitian children. Nature 600, 133\u2013137 (2021).","journal-title":"Nature"},{"key":"50931_CR38","unstructured":"Enanta Pharmaceuticals, Inc. NCT05616728. A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19 (SPRINT). (2022)."},{"key":"50931_CR39","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1021\/acsmedchemlett.2c00332","volume":"13","author":"CSB Chia","year":"2022","unstructured":"Chia, C. S. B. & See, Y. Y. Novel Coronavirus Main Protease Di- and Tripeptide Inhibitors for Treating COVID-19. ACS Med. Chem. Lett. 13, 1388\u20131389 (2022).","journal-title":"ACS Med. Chem. Lett."},{"key":"50931_CR40","doi-asserted-by":"publisher","first-page":"12725","DOI":"10.1021\/acs.jmedchem.0c01063","volume":"63","author":"RL Hoffman","year":"2020","unstructured":"Hoffman, R. L. et al. Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19. J. Med Chem. 63, 12725\u201312747 (2020).","journal-title":"J. Med Chem."},{"key":"50931_CR41","doi-asserted-by":"publisher","first-page":"e2025866118","DOI":"10.1073\/pnas.2025866118","volume":"118","author":"X He","year":"2021","unstructured":"He, X. et al. Generation of SARS-CoV-2 reporter replicon for high-throughput antiviral screening and testing. Proc. Natl. Acad. Sci. USA 118, e2025866118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"50931_CR42","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.3390\/v15061281","volume":"15","author":"JQ Khan","year":"2023","unstructured":"Khan, J. Q. et al. Generation of a SARS-CoV-2 Reverse Genetics System and Novel Human Lung Cell Lines That Exhibit High Virus-Induced Cytopathology. Viruses 15, 1281 (2023).","journal-title":"Viruses"},{"key":"50931_CR43","doi-asserted-by":"publisher","first-page":"7867","DOI":"10.1074\/jbc.M305645200","volume":"279","author":"MF De Rosa","year":"2004","unstructured":"De Rosa, M. F., Sillence, D., Ackerley, C. & Lingwood, C. Role of multiple drug resistance protein 1 in neutral but not acidic glycosphingolipid biosynthesis. J. Biol. Chem. 279, 7867\u20137876 (2004).","journal-title":"J. Biol. Chem."},{"key":"50931_CR44","doi-asserted-by":"publisher","first-page":"4914","DOI":"10.1002\/jps.21756","volume":"98","author":"AS Kalgutkar","year":"2009","unstructured":"Kalgutkar, A. S. et al. N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a \u2018chemical knock-out equivalent\u2019 to assess the impact of efflux transporters on oral drug absorption in the rat. J. Pharm. Sci. 98, 4914\u20134927 (2009).","journal-title":"J. Pharm. Sci."},{"key":"50931_CR45","doi-asserted-by":"publisher","first-page":"4380","DOI":"10.1016\/j.cell.2021.06.008","volume":"184","author":"H Zhou","year":"2021","unstructured":"Zhou, H. et al. Identification of novel bat coronaviruses sheds light on the evolutionary origins of SARS-CoV-2 and related viruses. Cell 184, 4380\u20134391.e14 (2021).","journal-title":"Cell"},{"key":"50931_CR46","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1126\/science.abi4506","volume":"373","author":"DR Martinez","year":"2021","unstructured":"Martinez, D. R. et al. Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice. Science 373, 991\u2013998 (2021).","journal-title":"Science"},{"key":"50931_CR47","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1038\/s41564-023-01476-x","volume":"8","author":"YJ Hou","year":"2023","unstructured":"Hou, Y. J. et al. Host range, transmissibility and antigenicity of a pangolin coronavirus. Nat. Microbiol 8, 1820\u20131833 (2023).","journal-title":"Nat. Microbiol"},{"key":"50931_CR48","doi-asserted-by":"publisher","first-page":"eadg5567","DOI":"10.1126\/scitranslmed.adg5567","volume":"15","author":"LV Tse","year":"2023","unstructured":"Tse, L. V. et al. A MERS-CoV antibody neutralizes a pre-emerging group 2c bat coronavirus. Sci. Transl. Med. 15, eadg5567 (2023).","journal-title":"Sci. Transl. Med."},{"key":"50931_CR49","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/s41586-020-2342-5","volume":"583","author":"SF Sia","year":"2020","unstructured":"Sia, S. F. et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature 583, 834\u2013838 (2020).","journal-title":"Nature"},{"key":"50931_CR50","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1093\/cid\/ciaa644","volume":"71","author":"JF Chan","year":"2020","unstructured":"Chan, J. F. et al. Simulation of the Clinical and Pathological Manifestations of Coronavirus Disease 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications for Disease Pathogenesis and Transmissibility. Clin. Infect. Dis. 71, 2428\u20132446 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"50931_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17367-2","volume":"11","author":"M Richard","year":"2020","unstructured":"Richard, M. et al. SARS-CoV-2 is transmitted via contact and via the air between ferrets. Nat. Commun. 11, 3496 (2020).","journal-title":"Nat. Commun."},{"key":"50931_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40556-8","volume":"14","author":"RM Cox","year":"2023","unstructured":"Cox, R. M. et al. Comparing molnupiravir and nirmatrelvir\/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models. Nat. Commun. 14, 4731 (2023).","journal-title":"Nat. Commun."},{"key":"50931_CR53","unstructured":"Del La Rosa, G. EDP-235, an Oral, Once Daily, Ritonavir-Free, 3CL Protease Inhibitor for the Treatment of COVID-19: Results from Phase 1 Study in Healthy Subjects. (2023)."},{"key":"50931_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26760-4","volume":"12","author":"RM Cox","year":"2021","unstructured":"Cox, R. M. et al. Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets. Nat. Commun. 12, 6415 (2021).","journal-title":"Nat. Commun."},{"key":"50931_CR55","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/s41564-023-01356-4","volume":"8","author":"SS Toussi","year":"2023","unstructured":"Toussi, S. S., Hammond, J. L., Gerstenberger, B. S. & Anderson, A. S. Therapeutics for COVID-19. Nat. Microbiol 8, 771\u2013786 (2023).","journal-title":"Nat. Microbiol"},{"key":"50931_CR56","unstructured":"Enanta Pharmaceuticals, Inc. SPRINT Data Presentation. (2023)."},{"key":"50931_CR57","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1001\/jama.2020.0757","volume":"323","author":"CI Paules","year":"2020","unstructured":"Paules, C. I., Marston, H. D. & Fauci, A. S. Coronavirus Infections\u2014More Than Just the Common Cold. JAMA 323, 707\u2013708 (2020).","journal-title":"JAMA"},{"key":"50931_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39782-x","volume":"14","author":"A Feng","year":"2023","unstructured":"Feng, A. et al. Transmission of SARS-CoV-2 in free-ranging white-tailed deer in the United States. Nat. Commun. 14, 4078 (2023).","journal-title":"Nat. Commun."},{"key":"50931_CR59","unstructured":"CDC. COVID-19 and Your Health. Centers for Disease Control and Prevention https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/daily-life-coping\/animals.html (2020)."},{"key":"50931_CR60","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.medj.2023.08.001","volume":"4","author":"Y Hirotsu","year":"2023","unstructured":"Hirotsu, Y. et al. Multidrug-resistant mutations to antiviral and antibody therapy in an immunocompromised patient infected with SARS-CoV-2. Med 4, 813\u2013824.e4 (2023).","journal-title":"Med"},{"key":"50931_CR61","doi-asserted-by":"publisher","unstructured":"Sanderson, T. et al. A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes. Nature 1\u20133. https:\/\/doi.org\/10.1038\/s41586-023-06649-6. (2023)","DOI":"10.1038\/s41586-023-06649-6"},{"key":"50931_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28354-0","volume":"13","author":"R Abdelnabi","year":"2022","unstructured":"Abdelnabi, R. et al. The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern. Nat. Commun. 13, 719 (2022).","journal-title":"Nat. Commun."},{"key":"50931_CR63","doi-asserted-by":"publisher","first-page":"eabq4064","DOI":"10.1126\/scitranslmed.abq4064","volume":"15","author":"M Sasaki","year":"2023","unstructured":"Sasaki, M. et al. S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters. Sci. Transl. Med. 15, eabq4064 (2023).","journal-title":"Sci. Transl. Med."},{"key":"50931_CR64","doi-asserted-by":"publisher","first-page":"398","DOI":"10.30802\/AALAS-CM-21-000036","volume":"71","author":"AM Braxton","year":"2021","unstructured":"Braxton, A. M. et al. Hamsters as a Model of Severe Acute Respiratory Syndrome Coronavirus-2. Comp. Med. 71, 398\u2013410 (2021).","journal-title":"Comp. Med."},{"key":"50931_CR65","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41564-020-00835-2","volume":"6","author":"RM Cox","year":"2021","unstructured":"Cox, R. M., Wolf, J. D. & Plemper, R. K. Therapeutically administered ribonucleoside analogue MK-4482\/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nat. Microbiol. 6, 11\u201318 (2021).","journal-title":"Nat. Microbiol."},{"key":"50931_CR66","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1057\/s41599-021-00710-3","volume":"8","author":"R Clair","year":"2021","unstructured":"Clair, R., Gordon, M., Kroon, M. & Reilly, C. The effects of social isolation on well-being and life satisfaction during pandemic. Humanit Soc. Sci. Commun. 8, 28 (2021).","journal-title":"Humanit Soc. Sci. Commun."},{"key":"50931_CR67","doi-asserted-by":"publisher","first-page":"12120","DOI":"10.3390\/ijerph191912120","volume":"19","author":"A Jeffers","year":"2022","unstructured":"Jeffers, A. et al. Impact of Social Isolation during the COVID-19 Pandemic on Mental Health, Substance Use, and Homelessness: Qualitative Interviews with Behavioral Health Providers. IJERPH 19, 12120 (2022).","journal-title":"IJERPH"},{"key":"50931_CR68","first-page":"406","volume":"21","author":"A Mullard","year":"2022","unstructured":"Mullard, A. Pfizer\u2019s small-molecule antiviral misses on COVID prevention. Nat. Rev. Drug Discov. 21, 406\u2013406 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"50931_CR69","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jinf.2023.08.016","volume":"87","author":"SA Alpizar","year":"2023","unstructured":"Alpizar, S. A. et al. Molnupiravir for intra-household prevention of COVID-19: The MOVe-AHEAD randomized, placebo-controlled trial. J. Infect. 87, 392\u2013402 (2023).","journal-title":"J. Infect."},{"key":"50931_CR70","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1021\/acsinfecdis.9b00012","volume":"5","author":"PJ Tonge","year":"2019","unstructured":"Tonge, P. J. Quantifying the Interactions between Biomolecules: Guidelines for Assay Design and Data Analysis. ACS Infect. Dis. 5, 796\u2013808 (2019).","journal-title":"ACS Infect. Dis."},{"key":"50931_CR71","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1126\/science.abf4830","volume":"371","author":"CG Rappazzo","year":"2021","unstructured":"Rappazzo, C. G. et al. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. Science 371, 823\u2013829 (2021).","journal-title":"Science"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50931-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50931-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50931-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T20:39:09Z","timestamp":1722544749000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50931-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["50931"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-50931-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,1]]},"assertion":[{"value":"21 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.H.J.R., A.C.R., A.B., N.B., N.M.K., J.S.G., J.L., M.V., T.C., M.C., R.S., N.M., J.C., R.E.L., D.L., T.Z., L.J., K.D., G.W., B.G, and Y.S.O. are either current or former employees of Enanta Pharmaceuticals and received salary and stock compensation during this study. R.M.C., C.M.L, J.D.W, R.K.P., S.R.L., T.S., and R.S.B. received funding from Enanta Pharmaceuticals. R.K.P. reports contract testing from Atea Pharmaceuticals and research support from Gilead Sciences, outside of the described work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6503"}}